| 期刊簡介 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | NATURE REVIEWS MOLECULAR CELL BIOLOGY LetPub Score 9.6
51 ratings
Rate
Reputation 10.0 Influence 9.7 Speed 7.1 | ||||||||||||||||||||
| 期刊簡稱 | NAT REV MOL CELL BIO | ||||||||||||||||||||
| ISSN | 1471-0072 | ||||||||||||||||||||
| E-ISSN | 1471-0080 | ||||||||||||||||||||
| h-index | 386 | ||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||
| 自引率 (2023-2024) | 0.40%自引率趨勢 | ||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||
| 官方網站 | https://www.nature.com/nrm | ||||||||||||||||||||
| 在線稿件提交 | https://mts-nrm.nature.com/ | ||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||
| 出版商 | Springer Nature | ||||||||||||||||||||
| 主題領域 | 生物 | ||||||||||||||||||||
| 出版國/地區 | ENGLAND | ||||||||||||||||||||
| 發行頻率 | 月刊 | ||||||||||||||||||||
| 創刊年 | 2000 | ||||||||||||||||||||
| 每年文章數 | 52每年文章數趨勢 | ||||||||||||||||||||
| 黃金OA百分比 | 1.37% | ||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q1
| ||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1471-0072%5BISSN%5D | ||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Mostly invited contributions | ||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [NATURE REVIEWS MOLECULAR CELL BIOLOGY] 的評論 | 撰寫評論 |
| 作者: TT 領域: 審稿時間: 0.0 month(s) 結果: 拒稿 撰寫評論 |
2024-08-06 11:23:26 評論於 Professional editors with constructive comments  (0) 讚！ | TT  |
| 作者: Life_IEEEFellow 領域: 生物学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-05-11 15:24:38 評論於 I would like to inquire about the experience of submitting contributions. Thank you. (0) 讚！ | Life_IEEEFellow |
| 作者: chaos and fractals 領域: 生物学 審稿時間: 6.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-04-13 17:45:09 評論於 2021.10.1 Submission 2022.2.25 Major revision 2022.4.12 Accept Overall, it is still acceptable. The entire research group has been working on this challenging issue. There is no communication with academicians from the Chinese Academy of Sciences, and the review comments are quite strict. Only papers with significant innovation can be submitted for review. Without prior experience, one paper was rejected. (34) 讚！ | chaos and fractals |
| 作者: guangyouyin 領域: 生物学 審稿時間: 2.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-02-18 11:18:54 評論於 Not knowing until I checked, I was startled when I did. (0) 讚！ | guangyouyin |
| 作者: 科研狗就是我 領域: 化学 審稿時間: 1.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-01-05 21:13:45 評論於 I actually ran all the way here to see this magazine. I'm floating, I have a high fever... (4) 讚！ | 科研狗就是我 |
| 作者: 维尔娜菲茨杰拉德 領域: 生物学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 19:48:03 評論於 A Protocol is a type of research article published in journals, generally a commentary or review by experts in the field on some hot topics or new research findings (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 维尔娜菲茨杰拉德 領域: 生物学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 10:39:26 評論於 A research article is the main type of article published in journals, generally longer in length and containing a large amount of research data. Compared to other types of articles, if it is basic research, the evidence chain will be sufficient and complete (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 平原文波 領域: 生物学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-28 12:48:51 評論於 What are the differences between a research article and other types of articles? (0) 讚！ | 平原文波 |
| 作者: 魂魄彦露 領域: 生物学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-26 22:16:42 評論於 What is Protocol? (0) 讚！ | 魂魄彦露 |
| 作者: 凌霄高洁 領域: 生物学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-07-16 17:13:27 評論於 Who can predict how many points there will be next year? (0) 讚！ | 凌霄高洁 |
| 作者: 匿名 領域: 審稿時間: 0.0 month(s) 結果: 撰寫評論 |
2011-08-19 13:02:00 評論於 Journal Homepage: http://www.nature.com/nrm/index.html (0) 讚！ | 匿名 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
